The Longevity Podcast: Alzheimer's and Brain Health Research

Send us Fan Mail

Alzheimer’s has been treated like a neuron problem for decades, but what if the real lever sits in the brain’s support system, quietly failing long before symptoms show up? We dig into a 2026 Journal of Prevention of Alzheimer’s Disease paper that uses a massive transcriptomic dragnet across multiple human datasets to spotlight one surprising hub: CD44, a receptor best known outside the brain, now showing up as a major signal across vulnerable Alzheimer’s regions.

We walk through why amyloid plaque clearing therapies can slow decline yet still come with modest benefit and serious tradeoffs like ARIA, frequent infusions, and intensive monitoring. Then we follow the evidence trail: region-by-region gene expression analysis, network hub logic, convergent functional genomic ranking, and the clinical “timeline paradox” where CD44 spikes in asymptomatic Alzheimer’s but does not neatly track with later cognitive severity. That pattern pushes us to treat CD44 as an early priming event, not a late-stage scar.

The biggest shift comes from single-nucleus RNA sequencing. CD44 is not coming from dying neurons. It is concentrated in astrocytes, particularly a neurotoxic reactive subpopulation tied to impaired autophagy, the brain’s protein waste recycling system. Using cell-to-cell communication modeling, the paper implicates microglial osteopontin (SPP1) signaling into astrocyte CD44, potentially jamming intracellular transport and stalling autophagic “garbage trucks.” We also cover the Petri-dish validation where CD44 knockdown restores autophagic flux markers and CD44 overexpression makes them worse.

If you care about Alzheimer’s disease research, astrocytes, microglia, autophagy, and next-generation therapeutic targets beyond amyloid, this is the map. Subscribe, share this with a friend who follows neuroscience, and leave a review with your take: should the next wave of trials prioritize restoring brain cleanup over clearing plaques?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Imagine learning that your brain is on a specific trajectory toward memory loss and you find out from a routine blood draw, not a spinal tap, not a hard-to-access PET scan. That future is arriving fast, and it’s creating a new challenge: we don’t have one “Alzheimer’s blood test” anymore. We have a growing menu of brain biomarkers, each reporting on a different kind of cellular crisis, and the only way to use them well is to match the marker to the underlying biology.

We walk through four of the biggest names in blood-based dementia diagnostics and brain health monitoring: p-tau217, p-tau181, NFL (neurofilament light chain), and GFAP. You’ll learn what each protein normally does, what it means when it shows up in plasma, and how ultrasensitive Simoa technology can measure these signals at almost unimaginable concentrations. Then we dig into a rigorous 2026 study that compares two very different cohorts, a South Korean memory clinic group and the North American ADNI research cohort, to test whether these biomarkers hold up across demographics, education levels, and disease stages.

The headline finding is a true plot twist: amyloid status flips the winners. In amyloid-positive people, p-tau217 emerges as the strongest predictor of cognitive decline, while GFAP can be a dominant signal for brain atrophy in symptomatic patients. In amyloid-negative people, NFL becomes the most reliable indicator of neurodegeneration and overall cognitive worsening, pointing to non-Alzheimer’s causes where general axonal injury is the key story. If you care about early Alzheimer’s detection, precision neurology, or the future of dementia screening, this is the framework to know. Subscribe, share this with someone navigating memory concerns, and leave a review with the biomarker question you want answered next.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

You can “pass” a memory test and still reveal something chilling: your brain can confidently invent a word that was never said. We start there because that tiny intrusion error, caught by the right kind of neuropsychological scoring, may be one of the earliest objective signals of Alzheimer’s disease long before you lose your keys or miss an appointment.

We unpack a 2026 narrative review that argues Alzheimer’s isn’t a sudden drop from healthy to sick, but a decades-long biological process. The centerpiece is Objectively Defined Subtle Cognitive Decline (ObjSCD), a new stage between cognitively normal aging and mild cognitive impairment. We explain the actuarial criteria behind it, why “process scores” matter as much as total scores on tests like the Ray Auditory Verbal Learning Test, and how longitudinal ADNI data links these subtle patterns to higher rates of progression to MCI and dementia. We also dig into the compounding role of type 2 diabetes, showing how metabolic and inflammatory stress can accelerate decline.

Then we go under the hood with the ATN framework and modern biomarkers: amyloid PET findings, tau biology, early structural changes like entorhinal cortex thinning, white matter damage, and the surprising spike in cerebral blood flow that suggests the brain is compensating before it collapses. We close with what could make early detection scalable: blood-based biomarkers such as p-tau217 and NfL paired with short digital cognitive screens, plus the hard equity question of building algorithms on narrow datasets.

If a simple blood draw and a 10-minute iPad test could predict Alzheimer’s risk decades early, would you want to know? Subscribe, share this with someone who thinks about brain health, and leave a review with your answer.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Your shoulders creep toward your ears during a brutal month. Your chest tightens during panic. Your body feels heavy during depression. We usually call those downstream symptoms, but the research we’re unpacking argues for something far more disruptive: fascia may help generate the very emotional states we blame on the brain alone.

We walk through a major 2026 review that reframes fascia as a continuous, body-wide sensory network rather than inert “wrapping paper.” From superficial fascia under the skin to deep fascia that transmits force, visceral fascia that lets organs glide, and parietal fascia that shapes the felt boundaries of the body, the anatomy sets the stage for the mental health link. Then we zoom into neurology: roughly 250 million nerve endings feeding interoception and proprioception, creating the quiet background signal that can register as safety, grounding, and mood.

From there, we trace the mechanism from chronic stress, trauma, and insomnia to sympathetic overactivity, ischemia, inflammation, TGF beta 1 signaling, and fibroblasts shifting into contractile myofibroblasts. Add hyaluronic acid densification and you get a stiff, sticky matrix that can distort afferent input into “interoceptive noise.” We connect that noise to anxiety, depression, altered pain perception, and findings from TMS studies that suggest reduced cortical inhibition. Finally, we get practical: mechanotransduction through sustained stretching, myofascial release, yoga, and somatic meditation, plus the role of diaphragmatic breathing and the vagus nerve in restoring parasympathetic balance.

If you’ve ever felt like your body won’t let your mind calm down, this deep dive is for you. Subscribe, share this with someone who lives in tension, and leave a review with one question you want answered next.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

What if the clearest signal about your brain’s future isn’t hidden inside an MRI, but floating in your blood right now? We dig into Neurofilament Light Chain (NFL), a nervous system biomarker that behaves like a smoke alarm for ongoing nerve damage and could help shift brain health from reactive to proactive.

We anchor the story in a remarkable study of 495 Japanese centenarians followed for up to 17 years. Researchers measured amyloid beta, phosphorylated tau, and NFL, and NFL came out on top for predicting cognitive function and mortality risk. That result forces a bigger rethink: clearing plaques may not be the same thing as slowing structural wear and tear across the brain and spinal cord, which helps explain why some Alzheimer’s drugs show modest cognitive benefits even when they hit their biological target.

From there, we break down the actual biology in plain language. Axons are long “cables,” NFL is part of their internal scaffolding, and when those cables degrade, NFL leaks into cerebrospinal fluid and then into the bloodstream. New ultrasensitive blood assays like Quanterix Simoa make it measurable without a spinal tap, opening the door to cheaper, repeatable tracking that can respond in weeks, not years.

We also get practical about how to use an NFL blood test wisely: why the trend line matters more than a single number, why you should avoid testing right after intense exercise, how obesity can falsely “lower” NFL via dilution, and which health factors tend to push NFL higher (sleep apnea, hypertension, diabetes, kidney disease, inflammation). We close with where this is heading next: tiered screening and “triggered prevention,” plus the open questions about baselines across different populations.

If you found this useful, subscribe, share it with someone who cares about brain health, and leave a review. What would you want to learn from your own NFL trajectory?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

You’ve heard the standard dementia prevention script: eat well, sleep more, do the puzzles, and hope for good genes. Then a result lands that doesn’t fit the script at all, a routine shingles vaccine associated with a 33% lower risk of dementia in a real-world study of 1.5 million Medicare patients. We dig into what that finding does and does not mean, why it’s so hard to dismiss, and how it compares to the modest wins medicine has chased for decades with expensive Alzheimer’s drugs. 

From there, we follow the science into the infection hypothesis and the surprisingly consistent epidemiology linking herpes viruses to cognitive decline. We talk HSV1 in the brain, the APOE4 connection, and the registry data showing dementia risk rising after severe herpes infections and falling with antiviral treatment. Then we flip the usual amyloid story on its head: amyloid plaques may act like an ancient antimicrobial defense, trapping pathogens like a biological cage, helpful in the short term and harmful when chronic reactivation keeps triggering more buildup. 

We also tackle the shingles puzzle with bioengineered brain tissue research suggesting shingles-related inflammation can “wake up” dormant HSV1 and spark Alzheimer’s-like changes. We zoom out to other viral evidence like EBV and MS, then bring it home with COVID-19 biomarker and imaging findings while keeping the risk in perspective. Finally, we translate all of this into action: shingles and flu vaccine data, what’s unsettled about COVID vaccination studies, and why an adjuvant called AS01 might be a key clue for immune-driven plaque cleanup. If this reshapes how you think about brain health, subscribe, share this with someone caring for aging parents, and leave a review with your biggest question about vaccines and dementia prevention.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Alzheimer’s has been sold to all of us as a neuron story: plaques, tangles, and brain cells fading away. But the data we walk through here points to a more unsettling possibility that the real tipping point is structural. When the brain’s blood vessels fail, memory can fall apart even faster, and what looks like “classic Alzheimer’s dementia” may actually be a vascular collapse hiding in plain sight.

We unpack a large autopsy analysis from the NACC database and use it to zoom in on cerebral amyloid angiopathy (CAA), where amyloid beta doesn’t just sit in brain tissue but builds up inside vessel walls. That shift changes everything. We explain the amyloid overflow hypothesis, how perivascular drainage pathways get overwhelmed with age, and why brittle arteries can set off microinfarcts that quietly sever brain networks over years. We also dig into a key double dissociation: CAA drives cortical microinfarcts, while hypertension-related arteriolosclerosis drives deep subcortical injury, meaning blood pressure control is essential but not the whole answer for Alzheimer’s-related vascular damage.

Then we go one layer deeper into genetics and the neurovascular unit. APOE ε4 shows up not only as an amyloid risk factor, but as a threat to blood-brain barrier integrity, letting proteins like fibrinogen leak into the brain and ignite microglia-driven inflammation. Finally, we connect these mechanisms to the new era of anti-amyloid monoclonal antibodies, ARIA risk, and why clearing plaques without accounting for “the state of the pipes” may limit real-world cognitive benefit.

If this reframes how you think about Alzheimer’s disease, vascular dementia, CAA, microinfarcts, and precision medicine, subscribe, share this with a friend, and leave a review. What do you think matters more for preventing dementia: removing amyloid or protecting brain blood vessels?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A medical breakthrough can still fail at the pharmacy counter. We finally have amyloid-targeting drugs for early-stage Alzheimer’s disease, and they are already on the market, but several major health systems have looked at the same evidence and refused to pay. That contradiction is the mystery we unpack, using the explosive Glasgow IPCAD meeting as our guide to what’s really blocking access.

We dig into the three barriers driving negative reimbursement decisions: headline drug prices, serious safety risks that require ongoing MRI monitoring, and the hardest problem of all, long-term efficacy. When trials last about 18 months, payers are forced to guess whether small changes in cognitive scores translate into years of real independence. From there, we explore the new toolkit health economists are building, including AI-supported micro-simulation models that create thousands of virtual patients and project outcomes decades into the future.

The conversation turns practical fast. We explain why caregiver burden and caregiver quality of life can change the math, why biomarker diagnostics like PET scans and lumbar punctures can bankrupt a system before the first dose, and how real-world evidence programs like coverage with evidence development try to balance access with learning. We also look at global registry efforts such as INRAD that standardize data across borders, then confront the uncomfortable truth: even if the money shows up, many countries lack the infusion clinics, diagnostic capacity, and specialist workforce to deliver these therapies at scale.

We close with a provocative question about the near future of blood-based screening and presymptomatic diagnosis, and what it means to know you’re at risk while treatment remains financially out of reach. If this helped you think differently about Alzheimer’s policy, health economics, and brain health, subscribe, share the episode, and leave a review so more people can find it.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A camera watches you walk across a room and can estimate your biological age. That sounds like science fiction until you see the data and the logic behind it. We break down a 2026 multidimensional modeling study that replaces the idea of “age as a number” with age as measurable wear and tear across your body and brain, using tools that are surprisingly practical: a marker-free 3D gait camera, a VR eye-tracking test, a soft fNIRS cap for brain connectivity, and a simple blood draw.

We start with gait analysis and the overlooked detail that matters more than speed: stride length. A shorter stride can be a clean signal of declining stability, joint flexibility, muscle power, and neuromuscular coordination. Then we move to eye movements, where pro-saccade reaction time becomes one of the strongest single predictors of aging, while smooth pursuit can stay stable thanks to compensatory plasticity. From there, we go under the hood with functional near-infrared spectroscopy to map resting-state functional connectivity, spotlighting Brodmann Area 10 (BA10) and why changes in this “conductor” region may show up as slower adaptation and harder multitasking.

Finally, we hit the molecular layer with two neurodegenerative biomarkers: GFAP and NFL. The pattern is nuanced and hopeful, pointing toward chronic low-grade inflammation (“inflammaging”) without implying that healthy aging automatically equals active neuronal destruction. When all four domains are combined with machine learning (XGBoost), the multimodal biological age clock becomes dramatically more accurate than many DNA methylation clocks, reinforcing a core lesson from longevity research: aging is never just one system.

If this kind of non-invasive biological age testing becomes common, smart homes and everyday headsets could turn into ambient health monitoring tools, raising big questions about privacy and data security alongside huge opportunities for preventive care. Subscribe for more deep dives, share this with someone who cares about aging well, and leave a review telling us which signal you trust most: gait, eyes, brain connectivity, or blood.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Depression and dementia get talked about like two separate problems, until you ask the uncomfortable question: which one comes first? We dig into a huge 22-year longitudinal study (over 13,000 Americans in the Health and Retirement Study) to figure out whether depressive symptoms are a modifiable dementia risk factor or an early clinical warning sign of Alzheimer’s disease and related neurodegenerative pathology.

The timeline turns out to be the tell. When depressive symptoms show up in late midlife (ages 50 to 59), dementia risk jumps dramatically, and the relationship holds even after researchers exclude people who develop dementia within the next 5 or 10 years. That pattern fits a long-run “rust” model, where chronic HPA axis activation, cortisol exposure, inflammation, and vascular damage slowly reduce brain resilience and cognitive reserve. When depression appears later (60+), the association fades with lag tests, pointing toward a prodrome like a check engine light rather than decades of wear-and-tear.

Then the genetics twist lands: depression predicts incident dementia most strongly in people with lower Alzheimer’s polygenic risk scores, while it barely moves the needle for those with high genetic risk. We also unpack a Markov model of cognitive stages, including the controversial gray zone of subjective memory complaint, and why new depression during that stage can matter so much clinically.

If you care about dementia prevention, mental health, or aging well, this conversation gives you a clearer map for action by age and risk profile. Subscribe for more deep dives, share this with someone navigating depression or memory worries, and leave a review with your biggest takeaway.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!